Pulse Biosciences (NASDAQ:PLSE) Reaches New 52-Week High – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) reached a new 52-week high on Tuesday . The company traded as high as $34.00 and last traded at $33.7360, with a volume of 16031 shares changing hands. The stock had previously closed at $32.79.

Wall Street Analyst Weigh In

PLSE has been the subject of a number of recent research reports. Canaccord Genuity Group initiated coverage on Pulse Biosciences in a report on Thursday, June 4th. They issued a “buy” rating and a $32.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Pulse Biosciences Trading Up 2.1%

The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -30.37 and a beta of 1.65. The company has a 50 day moving average price of $26.90 and a 200 day moving average price of $22.27.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.25 million. Equities analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan purchased 660,233 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the completion of the purchase, the director directly owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul A. Laviolette purchased 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $19.69 per share, with a total value of $295,350.00. Following the completion of the purchase, the chief executive officer owned 15,000 shares of the company’s stock, valued at $295,350. The trade was a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 74.00% of the stock is owned by insiders.

Institutional Trading of Pulse Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Pulse Biosciences by 44.0% during the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after purchasing an additional 1,372 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the second quarter worth $158,000. Finally, Brevan Howard Capital Management LP bought a new stake in Pulse Biosciences in the second quarter valued at about $215,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.